These data indicate that EPAC-1 is a pivotal regulator of endothelial function in (diabetic) microangiopathies involving endothelial dysfunction associated with hypoxia, and might serve as promising therapeutic targets to ameliorate these conditions. Here, RAPGEF3 is linked to endothelial dysfunction.